本文通过传染病报告系统和麻疹监测系统收集数据，选择上海2009－2017年麻疹实验室确诊病例中具有明确免疫接种史的麻疹免疫失败病例，对其特征进行描述性分析，同时采用麻疹病毒IgG亲和力检测方法，对监测剩余血清进行检测，分析平均相对亲和力指数(Relative avidity index，RAI) 和不同人群中高/可疑/低亲和力比例。在253例具有明确免疫史的麻疹实验室确诊病例中，男女比例为1：1.72（160/93），IgG阳性的麻疹病例中，IgG 高、低、可疑亲和力分别占 53.99%、24.54%、21.47%。不同年龄分组高亲和力病例比例呈波浪式升高下降分布，1-19岁人群人数分布最高，20-29岁人群略有下降，30~39岁患者中高亲和力病例占此年龄层比例最高，为76.9%。0 剂次、1 剂次、≥2 剂次含麻疹成分疫苗（ Measles containing vaccine，MCV） 免疫史病例高亲和力比例分别为11.71%（41/350）、26.6%（51/192）、60.7%（37/61）。
Abstract
To analyze distribution characteristics of vaccination failure types among laboratory-confirmed cases of measles in Shanghai during 2009-2017, measles cases with confirmed vaccination document among the measles laboratory-confirmed cases in Shanghai from 2009 to 2017 were selected to conduct a descriptive study about their characteristics. Measles virus IgG avidity assay was used to analyse the average relative avidity index (RAI) and determined proportions of different groups with high/medium/low affinity ratio. Among the 253 laboratory-confirmed cases of measles with a clear history of immunity, the male to female ratio was 1:1.72 (160/93). Among these IgG-positive measles cases, IgG with high, low, and suspicious affinity accounted for 53.99%, 24.54%, and 21.47% respectively. The proportion of high-affinity cases across different age groups exhibits a wave-like pattern of increase and decrease. The 1-19 years age group has the highest number of cases, while the 20-29 years group shows a slight decline. Among patients aged 30-39 years, the proportion of high-affinity cases within this age group reached the highest percentage at 76.9%. 0 doses, 1 dose, ≥2 doses Measles containing vaccine, The proportions of high affinity cases with MCV) immunity history were 11.71%(41/350), 26.56% (51/192), and 60.65% (37/61) respectively.
关键词
麻疹 /
消除 /
免疫失败 /
抗体亲和力
Key words
measles /
elimination /
vaccination failure /
IgG antibody affinity
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1]王慧玲，许文波，张燕.中国麻疹消除进展. 中华医学杂志 2023; 103(26):2031-2036.
[2] eClinicalMedicine.Concerning global rise in measles cases. EClinicalMedicine 2024; 68:102502.
[3] WHO.Measles reported cases and incidence. 2024.
[4] (VIF) V-PDaI.Measles and rubella monthly update. 2024.
[5] Breakwell, L.Moturi, E.Helgenberger. et al. Measles Outbreak Associated with Vaccine Failure in Adults--Federated States of Micronesia, February-August 2014. MMWR Morb Mortal Wkly Rep 2015； 38（65）：1088-92.
[6] Paunio M, Hedman K, Davidkin I, Peltola H.IgG avidity to distinguish secondary from primary measles vaccination failures: prospects for a more effective global measles elimination strategy. Expert Opin Pharmacother 2003; 4(8):1215-1225.
[7] Rosen JB, Rota JS, Hickman CJ, Sowers SB, Mercader S, Rota PA, et al.Outbreak of measles among persons with prior evidence of immunity, New York City, 2011. Clin Infect Dis 2014; 58(9):1205-1210.
[8] Cassini A, Cobuccio L, Glampedakis E, Cherpillod P, Crisinel PA, Pérez-Rodríguez FJ, et al.Adapting response to a measles outbreak in a context of high vaccination and breakthrough cases: an example from Vaud, Switzerland, January to March 2024. Euro Surveill 2024; 29(22).
[9] 于霞丽，付茵，陈萌.IgG 抗体亲和力方法用于鉴别麻疹原发和继发性免疫失败. 中国疫苗和免疫 2017; 23(1):22-25.
[10] Ma R, Lu L, Zhangzhu J, Chen M, Yu X, Wang F, et al.A measles outbreak in a middle school with high vaccination coverage and evidence of prior immunity among cases, Beijing, P.R. China. Vaccine 2016; 34(15):1853-1860.
[11] Ding Y, Sun Y, Liu Y.A measles outbreak in a middle school with high vaccination coverage in Tianjin, 2016. Chinese Journal of Vaccines and Immunization 2016; 23:62-66.
[12] Kurata T, Kanbayashi D, Egawa K, Kinoshita M, Yoshida H, Miyazono M, et al.A measles outbreak from an index case with immunologically confirmed secondary vaccine failure. Vaccine 2020; 38(6):1467-1475.
[13] Zhang Z, Chen M, Ma R, Pan J, Suo L, Lu L.Outbreak of measles among persons with secondary vaccine failure, China, 2018. Hum Vaccin Immunother 2020; 16(2):358-362.
[14] Iwamoto M, Hickman CJ, Colley H, Arciuolo RJ, Mahle CE, Deocharan B, et al.Measles infection in persons with secondary vaccine failure, New York City, 2018-19. Vaccine 2021; 39(38):5346-5350.
[15] 杨玉颖，汤素文，唐伟，范佳磊，李智，杨佳炜，任佳，李崇山.上海市2010—2020年健康人群麻疹和风疹及流行性腮腺炎病毒抗体水平研究. 中华预防医学杂志 2022; 56(8):1095-1100.
[16] El Mubarak HS, Ibrahim SA, Vos HW, Mukhtar MM, Mustafa OA, Wild TF, et al.Measles virus protein-specific IgM, IgA, and IgG subclass responses during the acute and convalescent phase of infection. J Med Virol 2004; 72(2):290-298.
[17] 丁亚兴，毛乃颖，雷玥，曲江文，郭玉婷，刘莹.麻疹实验室确诊病例原发性和继发性免疫失败的回顾性研究. 中国疫苗和免疫; 27(5):514-518.
[18] Whittle HC, Aaby P, Samb B, Jensen H, Bennett J, Simondon F.Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa. Lancet 1999; 353(9147):98-102.
[19] Edmonson MB, Addiss DG, McPherson JT, Berg JL, Circo SR, Davis JP.Mild measles and secondary vaccine failure during a sustained outbreak in a highly vaccinated population. JAMA 1990; 263(18):2467-2471.
[20] Mitchell P, Turner N, Jennings L, Dong H.Previous vaccination modifies both the clinical disease and immunological features in children with measles. J Prim Health Care 2013; 5(2):93-98.
[21] Pannuti CS, Morello RJ, Moraes JC, Curti SP, Afonso AM, Camargo MC, et al.Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 S?o Paulo epidemic. Clin Diagn Lab Immunol 2004; 11(1):119-122.
[22] Keeling MJ, Grenfell BT.Understanding the persistence of measles: reconciling theory, simulation and observation. Proc Biol Sci 2002; 269(1489):335-343.
[23] Cui X, Li Y, Yang Y, Tang W, Li Z, Chen H, et al.Characteristics and Genomic Diversity of Measles Virus From Measles Cases With Known Vaccination Status in Shanghai, China. Front Med (Lausanne) 2022; 9:841650.
